Paraganglioma Cell Models for Research

Paragangliomas (PGL) are rare neuroendocrine tumors arising from chromaffin cells of the paraganglia. The annual incidence is estimated at 1-2 per 100,000 person-years, with a slight female predominance. Most PGLs are benign, but 10-20% metastasize, and the 5-year survival for metastatic disease is approximately 50% (NCI). The World Health Organization (WHO) classifies PGLs based on anatomic location (head and neck, thoracic, abdominal, pelvic) and genetic background. Hereditary forms account for 30-40% of cases, with germline mutations in SDHx genes (SDHA, SDHB, SDHC, SDHD) being the most common. The clinical impact is significant due to catecholamine excess, which can cause life-threatening hypertension, arrhythmias, and stroke. Surgical resection is the primary treatment, but for metastatic disease, no curative therapy exists, highlighting the need for novel therapeutic targets and model systems.

Paraganglioma is an ideal model for studying tumor metabolism, hypoxia signaling, and epigenetic dysregulation. The genetic landscape is well-defined, with mutations in SDHx genes leading to succinate accumulation and pseudohypoxia. Public datasets, such as TCGA (The Cancer Genome Atlas) and COSMIC, provide comprehensive genomic and transcriptomic data, enabling mechanistic studies. Open questions include the role of SDHx mutations in tumor initiation, the mechanisms of metastasis, and the development of targeted therapies. Gene-edited cell models, such as SDHB knockout or HIF2A reporter lines, are essential for dissecting these pathways and validating drug targets.

The pathogenesis of paraganglioma involves several key pathways:

1. Succinate Dehydrogenase (SDH) Pathway: Mutations in SDHx genes (SDHA, SDHB, SDHC, SDHD) lead to loss of SDH enzyme activity, causing accumulation of succinate. Succinate inhibits prolyl hydroxylases (PHDs), leading to stabilization of hypoxia-inducible factor 1-alpha (HIF1A) and 2-alpha (HIF2A), resulting in a pseudohypoxic response.

2. Hypoxia-Inducible Factor (HIF) Signaling: Stabilized HIF1A/HIF2A translocate to the nucleus and activate transcription of genes involved in angiogenesis (VEGF), glycolysis (GLUT1, LDHA), and cell proliferation (Cyclin D1). This pathway is central to tumor growth and survival.

3. PI3K/AKT/mTOR Pathway: Activation of this pathway promotes cell survival, proliferation, and metabolism. It is often upregulated in PGLs, especially in those with SDHB mutations.

4. Wnt/β-Catenin Pathway: Aberrant activation of Wnt signaling has been observed in a subset of PGLs, contributing to stemness and invasion.

Data from TCGA and COSMIC databases.

The deregulated signaling networks in paraganglioma include:

• • Pseudohypoxia Network: Key nodes include HIF1A, HIF2A, PHDs, and succinate. This network drives angiogenesis and metabolic reprogramming.
• • PI3K/AKT/mTOR Network: Key nodes include PI3K, AKT, mTOR, and PTEN. This network promotes cell growth and survival.
• • RAS/MAPK Network: Key nodes include RAS, RAF, MEK, and ERK. This network is activated in NF1-mutant tumors.
• • Wnt/β-Catenin Network: Key nodes include β-catenin, APC, and GSK3β. This network contributes to tumor stemness and invasion.
• • Epigenetic Regulation: SDHx mutations cause DNA hypermethylation via inhibition of TET enzymes, leading to silencing of tumor suppressor genes.

Organoid models derived from patient tumors are increasingly used to recapitulate the 3D architecture and tumor microenvironment. They retain the genetic heterogeneity of the original tumor and are useful for drug screening.

• • Patient-Derived Xenografts (PDX): Implantation of patient tumor tissue into immunodeficient mice. PDX models preserve the genetic and histological features of the original tumor and are used for drug efficacy testing.
• • Genetically Engineered Mouse Models (GEMM): Mice with targeted mutations in SDHB, SDHD, or VHL. These models develop pheochromocytoma/paraganglioma with variable penetrance and are useful for studying tumor initiation and progression.
• • Induced Models: Chemical or viral induction of tumors, such as subcutaneous injection of rat pheochromocytoma cells (PC12) into nude mice. These models are used for rapid tumor growth and drug screening.

CRISPR-based gene editing has revolutionized the generation of isogenic cell models for paraganglioma research. By introducing precise knockouts or knock-ins in relevant genes (e.g., SDHB, SDHD, VHL, HIF2A), researchers can create isogenic pairs that differ only in the target gene, enabling direct functional studies. For example, an SDHB knockout in a wild-type cell line recapitulates the metabolic and pseudohypoxic phenotype observed in SDHB-mutant tumors. Similarly, a HIF2A reporter line can be used to monitor hypoxia pathway activity in real time. These gene-edited models are commercially available from various sources and are sequence-verified to ensure accuracy. They accelerate research by providing reproducible, well-characterized tools for drug discovery, target validation, and functional genomics.

Gene-edited cells are essential for functional genomics studies. For example, an SDHB knockout line can be used to identify genes that become essential in the context of SDH deficiency, using CRISPR screens. This approach has revealed synthetic lethal partners, such as the DNA repair protein PARP1, which are now being explored as therapeutic targets. Similarly, a VHL knockout line can be used to study the role of VHL in HIF regulation and identify downstream effectors.

Isogenic cell line pairs are ideal for drug screening. By comparing the response of wild-type and mutant cells to a panel of compounds, researchers can identify drugs that specifically target the mutant phenotype. For example, SDHB knockout cells show increased sensitivity to inhibitors of the mitochondrial complex I, such as metformin, and to HIF2A inhibitors. Gene-edited models can also be used to study drug resistance mechanisms. For instance, prolonged exposure of SDHB knockout cells to a HIF2A inhibitor can select for resistant clones, which can then be analyzed to identify resistance mutations.

CRISPR synthetic lethality screens using gene-edited cells can identify novel biomarkers for diagnosis and prognosis. For example, by knocking out SDHB in a cell line and performing a genome-wide CRISPR screen, researchers can identify genes whose loss is lethal only in SDHB-deficient cells. These genes may serve as biomarkers for SDHB-mutant tumors. Additionally, gene-edited reporter lines can be used to monitor pathway activation, which can be used as a pharmacodynamic biomarker in drug development.